Targeted NGS analysis to predict recurrence in resected EGFR-mutated lung adenocarcinoma

被引：0
|
作者：
Kim, In Ae [1 ]
Kim, Hee Jung [1 ]
Hur, Jae Young [1 ]
Lee, Seung En [1 ]
Park, Jung Hoon [2 ]
Lee, Song Am [1 ]
Hwang, Jae Jun [1 ]
Kim, Wan Seop [1 ]
Lee, Kye Young [1 ]
机构：
[1] Konkuk Univ, Med Ctr, Seoul, South Korea
[2] Macrogen Inc, Seoul, South Korea
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-5896
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5896
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Achievement of pathological complete response with osimertinib for EGFR-mutated lung adenocarcinoma
    Fujita, Yasuhiro
    Take, Nobuyuki
    Shinohara, Shinji
    Mori, Masataka
    Kanayama, Masatoshi
    Takenaka, Masaru
    Kuroda, Koji
    Shimajiri, Shohei
    Tanaka, Fumihiro
    GENERAL THORACIC AND CARDIOVASCULAR SURGERY CASES, 2023, 2 (01):
  • [22] Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma
    Sun, Ruizhu
    Hou, Zhansheng
    Zhang, Yankui
    Jiang, Bo
    ONCOLOGY LETTERS, 2022, 24 (05)
  • [23] Severe cardiotoxicity induced by osimertinib in a patient with EGFR-mutated adenocarcinoma of the lung
    Tanaka, Takaaki
    Nii, Soma
    Yamaoka, Hidenaru
    Fujimoto, Nobukazu
    BMJ CASE REPORTS, 2023, 16 (07)
  • [24] Importance of "targeted therapy" in EGFR-mutated Lung Cancer after Radiochemotherapy
    Mueller, Joerg Andreas
    Vordermark, Dirk
    STRAHLENTHERAPIE UND ONKOLOGIE, 2024, 200 (10) : 921 - 923
  • [25] Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    John, Thomas
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu Thi
    Dechaphunkul, Arunee
    Kowalski, Dariusz
    Poole, Lynne
    Bolanos, Ana
    Rukazenkov, Yuri
    Wu, Yi-Long
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (02): : 137 - 147
  • [26] EGFR-Mutated Pulmonary Choriocarcinoma Combined With Adenocarcinoma
    Shigematsu, Yasuyuki
    Nakano, Kaoru
    Uchibori, Ken
    Inamura, Kentaro
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (11) : 1318 - 1322
  • [27] Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma
    Park, Sehhoon
    Shim, Joon Ho
    Lee, Boram
    Cho, Inju
    Park, Woong-Yang
    Kim, Youjin
    Lee, Se-Hoon
    Choi, Yoon La
    Han, Joungho
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Sun, Jong-Mu
    LUNG CANCER, 2019, 134 : 7 - 15
  • [28] Real-world outcome analysis of EGFR-mutated lung adenocarcinoma with brain metastases.
    Kuan, Fens-Che
    Yang, Wei-Hsun
    Lai, Hung-Yi
    Huang, Chun-Chieh
    Yang, Cheng-Ta
    Shi, Chung-Shang
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma
    Torasawa, Masahiro
    Yoshida, Tatsuya
    Shiraishi, Kouya
    Yagishita, Shigehiro
    Ono, Hanako
    Uehara, Yuji
    Miyakoshi, Jun
    Tateishi, Akiko
    Igawa, Yukiko Shimoda
    Higashiyama, Ryoko Inaba
    Mochizuki, Akifumi
    Masuda, Ken
    Matsumoto, Yuji
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Hamamoto, Ryuji
    Yamamoto, Noboru
    Watanabe, Shun-ichi
    Yatabe, Yasushi
    Takahashi, Kazuhisa
    Kohno, Takashi
    Ohe, Yuichiro
    LUNG CANCER, 2025, 202
  • [30] Proteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFR-mutated lung cancer
    Treue, Denise
    Bockmayr, Michael
    Stenzinger, Albrecht
    Heim, Daniel
    Hester, Svenja
    Klauschen, Frederick
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (03) : 545 - 557
12345